樂普生物-B(02157.HK)午後曾飆近3.9倍高見31.8元 本週一起獲深交所調入港股通名單
本週一(5日)起獲深交所調入港股通名單的樂普生物-B(02157.HK)今天(9日)價量齊呈異動,尤其是午後股價曾飆近3.9倍至31.8元上市新高遇阻,現報24.9元,仍飆2.8倍,一向稀疏成交急增至257萬股,創近半年高,涉資5,688萬元。
樂普生物是一家聚焦於腫瘤治療領域的創新型生物製藥企業,並已構建了多個產品管線。該股今年2月23日以每股7.13元來港上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.